Skip to Content

Raxibacumab Approval History

  • FDA approved: Yes (First approved December 14th, 2012)
  • Generic name: raxibacumab
  • Company: GlaxoSmithKline
  • Treatment for: Anthrax

Raxibacumab is a human monoclonal antibody drug for the treatment of inhalational anthrax.

Development History and FDA Approval Process for raxibacumab

Dec 14, 2012Approval FDA Approves Raxibacumab to Treat Inhalational Anthrax
Jul 10, 2012Human Genome Sciences Announces Resubmission of Raxibacumab BLA to FDA
Nov 16, 2009Human Genome Sciences Receives Complete Response Letter from FDA for Raxibacumab Biologics License Application
May 21, 2009Human Genome Sciences Submits Biologics License Application to FDA for ABthrax

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.